Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CAMP vs ACRS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACRS Captures Overall Composite Edge (44.7 HOLD vs 43.9 HOLD), While CAMP Leads 5–0 on Growth & Valuation Pillars

ACRS Overall Winner 6-Pillar Tally: CAMP 5 – 0 ACRS (1 Tie) Matrix Metrics: CAMP 2 – 5 ACRS

As of Nov 17, 2026, Aclaris Therapeutics, Inc. (ACRS) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (44.7/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 5–2 (led by composite factor balance), while CAMP wins 5–0 across the 6-pillar growth and valuation breakdown. CAMP trades at $3.95 (N/M Forward P/E, -991.8% operating margin) versus ACRS at $3.38 (N/M Forward P/E, -1412.4% operating margin).

  • Growth vs. Quality Trade-Off: ACRS earns the overall head-to-head edge with a stronger Unified Composite Score (44.7/100 HOLD vs. CAMP 43.9/100 HOLD) and 1.55β · 73% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9); meanwhile ACRS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAMP vs ACRS
CAMP NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$3.95
+2.33% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.34β · 94% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 34.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $3.82 · SMA50: $3.84
ACRS NASDAQ Head-to-Head Winner
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.38
-6.1% 1D
Market Cap $621.8M
TTM Revenue $6.4M
Forward P/E N/M
Beta / 30D Vol 1.55β · 73% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 41.0 Fund 54.0 Flow 64.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.3%), weak momentum, RSI 37
RSI-14: 37.0 · SMA20: $3.86 · SMA50: $4.33

6-Pillar Scorecard Institutional Category Breakdown (CAMP 5 – 0 ACRS)

Columns: Metric · CAMP · ACRS
1. Valuation Multiples CAMP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 26.6x 97.1x
2. Growth & Scale CAMP
Revenue Growth (YoY) +138.9% -55.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $5.3M $6.4M
Market Cap $238.5M $621.8M
3. Profitability & Quality CAMP
Gross Margin N/A N/A
Operating Margin -991.8% -1412.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -146.1% -55.5%
4. Balance Sheet & Cash Flow CAMP
Cash Generation (TTM) -$26M -$75M
Cash Flow Margin N/A N/A
Net Cash / Leverage $97M Net Cash $1.11 Book/Sh · -55.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAMP
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 60.7% (1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAMP (2) vs ACRS (5)
Institutional Metric CAMP ACRS Criterion Row Edge
Market Capitalization
Scale
$238.5M $621.8M Larger Scale ACRS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+138.9% -55.1% Higher Growth CAMP
Operating Margin (TTM)
Profitability
-991.8% -1412.4% Higher Margin CAMP
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-146.1% -55.5% Higher ROE ACRS
52-Week Range Position
Momentum
22% ($3–$8) 26% ($2–$7) Stronger Trend ACRS
Beta / 30D Volatility
Risk Regime
1.34β · 94% Vol 1.55β · 73% Vol Lower Realized Risk ACRS
Unified Institutional Score
Composite Signal
43.9 / 100 (HOLD) 44.7 / 100 (HOLD) Higher Composite ACRS
Trailing 12M Revenue (USD)
Operating Scale
$5.3M $6.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 26.6x EV/Rev N/M PEG · 97.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$26M ($97M Net Cash) -$75M ($1.11 Book/Sh · -55.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAMP +28.53 pp
CAMP: +25.8% · ACRS: -2.73%
3M Horizon CAMP +32.39 pp
CAMP: -15.05% · ACRS: -47.44%
6M Horizon CAMP +19.11 pp
CAMP: -4.82% · ACRS: -23.93%
1Y Horizon ACRS +37.99 pp
CAMP: -3.66% · ACRS: +34.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CAMP Revenue ACRS Revenue CAMP Op. Margin ACRS Op. Margin Margin Leader
FY2018 N/A $10M N/A -1378.3% ACRS
FY2019 N/A $0M N/A -2627.3% ACRS
FY2020 N/A $10M N/A -785.4% ACRS
FY2021 N/A $10M N/A -1327.1% ACRS
FY2022 N/A $30M N/A -302.0% ACRS
FY2023 $0M $30M -14822.6% -311.6% ACRS
FY2024 $0M $20M -8142.3% -758.2% ACRS
FY2025 $0M $10M -1502.4% -975.9% ACRS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACRS BREAKDOWN
130d in phase · OBV NEUTRAL
Current IV 60.7%
IV Percentile 1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ACRS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACRS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $621.8M market capitalization and -1412.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CAMP vs ACRS Key Questions & Quantitative Answers

As of Nov 17, 2026, Aclaris Therapeutics, Inc. (ACRS) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (44.7/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 5–2 (led by composite factor balance), while CAMP wins 5–0 across the 6-pillar growth and valuation breakdown. CAMP trades at $3.95 (N/M Forward P/E, -991.8% operating margin) versus ACRS at $3.38 (N/M Forward P/E, -1412.4% operating margin). Growth vs. Quality Trade-Off: ACRS earns the overall head-to-head edge with a stronger Unified Composite Score (44.7/100 HOLD vs. CAMP 43.9/100 HOLD) and 1.55β · 73% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9); meanwhile ACRS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CAMP leads the Growth & Scale pillar: CAMP posts +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin), compared with ACRS at -55.1% YoY revenue growth and +0.0% YoY earnings growth on $6.4M TTM revenue (N/A gross margin, -1412.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CAMP cumulative revenue shifted N/A while ACRS shifted +0.0%. In operating R&D and SG&A reinvestment, CAMP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACRS.

CAMP screens cheaper on headline valuation multiples. CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin), whereas ACRS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 97.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAMP (-146.1% ROE) versus ACRS (-55.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk). By comparison, ACRS carries 60.7% implied volatility (1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.55β · 73% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.